Comparative Pharmacology
Head-to-head clinical analysis: COPEGUS versus TRIFLURIDINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COPEGUS versus TRIFLURIDINE.
COPEGUS vs TRIFLURIDINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ribavirin is a nucleoside analogue that inhibits viral RNA synthesis by interfering with RNA capping and polymerase activity, and may also modulate immune responses.
Trifluridine is a thymidine analog that inhibits thymidylate synthase and incorporates into DNA, leading to DNA damage and cell death.
800 mg orally twice daily to 1200 mg orally twice daily based on body weight (≤75 kg: 800 mg; >75 kg: 1200 mg), in combination with ribavirin, for 24 to 48 weeks depending on genotype.
Topical: Apply one drop to affected eye every 2 hours while awake (maximum 9 drops/day) until re-epithelialization, then one drop every 4 hours for 7 days. Ophthalmic solution 1%.
None Documented
None Documented
Clinical Note
moderateTrifluridine + Digoxin
"Trifluridine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateTrifluridine + Digitoxin
"Trifluridine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateTrifluridine + Deslanoside
"Trifluridine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateTrifluridine + Acetyldigitoxin
"Trifluridine may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 120-170 hours following multiple doses, supporting once-daily dosing with prolonged viral suppression.
The terminal elimination half-life of trifluridine is approximately 12-18 hours. This prolonged half-life supports twice-daily dosing and provides sustained exposure for antiviral activity.
Ribavirin is primarily eliminated renally as unchanged drug (61%) and metabolites (30%); biliary/fecal excretion accounts for ~9%.
Renal excretion accounts for approximately 40-50% of the administered dose, primarily as the inactive metabolite 5-trifluorothymidine. Fecal excretion is minimal (<5%). The remainder is eliminated via metabolic degradation.
Category C
Category C
Antiviral
Antiviral